Adma Biologics Inc., of Ramsey, N.J., said it priced its underwritten public offering of 11.25 million shares of its common stock at $4 each, resulting in gross proceeds of approximately $45 million. The company has also granted the underwriters a 30-day option to purchase up to 1.68 million additional shares.